Our Management Team
Ross Morton
Managing Partner
Ross founded Nodenza and leads the Fund in identifying new investment opportunities, engaging with Limited Partners and day to day operations. He sits on the Investment Committee.
Ross was COO of Akaza Bioscience, sold to Aquarious Bio in 2022. Prior, he was on the management team of Izana Bioscience, which sold to one of the Roivant companies in 2020.
Previously, Ross was a management consultant in the Advisory practice at Kinapse, a Syneos company supporting Big Pharma R&D projects.
Expertise: Diligence & Financing
Bryan Morton
Chairman & Partner
Bryan is responsible for providing commercial expertise in evaluating potential & ongoing investments, as well as deal terms and negotiation strategy. He sits on the Investment Committee.
Previously the CEO and then Chairman of EUSA Pharma, CEO of Zeneus Pharma, and Chairman of Aircraft Medical, Bryan has a broad experience in development & commercial stage biotech & medical device companies.
He held senior management positions at Merck & Bristol Myers Squibb.
Expertise: Diligence & Financing
Dr Tim Corn
Partner
Tim oversees the Clinical & Regulatory needs of our investments. He sits on the Investment Committee.
A serial CMO, Tim has led the development, regulatory approval, and launch of 20+ products with the FDA and EMA.
Tim was the Chief Medical Officer at the highly successful Zeneus Pharma and EUSA Pharma. He now holds various industry Board seats.
He previously held positions at GSK, Elan, Jazz & the UK Medicines and Healthcare products Regulatory Agency.
Expertise: Clinical & Regulatory
Dr Dev Kumar
Partner
George Freeman MP
Chairman of the Advisory Board
Carsten Thiel
Advisory Board Member
Dev leads the Legal & Intellectual Property needs of portfolio companies. An expert in guiding the transaction and commercial aspects of investments, Dev sits on the Investment Committee.
Dev is dually qualified as a lawyer & medical doctor. He focuses on corporate, regulatory, and IP matters with a specialist interest in pricing & reimbursement.
Most recently General Counsel of EUSA Pharma, Dev now sits on various Boards.
He previously held positions at Biogen, UCB, Boehringer Ingelheim, & the University of Oxford.
Expertise: Market Access & Intellectual Property
Advisory Board
After a 15yr career in UK Life Science Venture finance - as Director of Early Stage Ventures at Merlin Biosciences 1997-2001, CEO of Amedis Pharma before its merger with Paradigm & sale to Takeda, and Founding CEO of 4D Biomedical - George was elected to Parliament in 2010 and has held a number of key Science & Technology Ministerial roles under 4 Prime Ministers over the last 14years, representing the UK at successive G7 & G20 Science Summits, overseeing the UK’s renegotiation to the European Horizon R+D & negotiating the UK’s S+T Collaborations with Canada, Japan, Israel & Switzerland.
As the UK’s first Minister for Life Science, George led the UK’s 10yr Life Science Industrial Strategy in 2011, launching Genomics England, the Dementia Research Institute, the Accelerated Access reforms, UK Clinical Trials
Carsten is a visionary leader with a strong science-based background with PhD in Molecular Biology from Max-Planck Institute. Carsten’s career has been commercially focused in both public and private companies with the highlight of generating >4x IRR with the successful exit of EUSA Pharma.
His core expertise lies in turning businesses around, driving significant top and bottom-line growth, managing small and large teams, M&A activities and integration, building, restructuring and revitalizing capability. He has a demonstrable record of driving hyper-growth at iconic companies through innovation and operational excellence, and guiding diverse, cross-functional teams.
Most recently, Carsten built out the rare disease capabilities at EUSA Pharma, restructured the company as CEO. In 2022 the company was acquired by RECORDATI.
Carsten has been recognized as one of “The Top 25 Healthcare Technology CEOs of Europe for 2021”